Analysis of Solid Tumor Indication Screening Success Rate of Zelin Bio's ZeniMind Platform

Based on systematic retrieval and analysis of publicly available information, the following professional analysis is provided regarding the solid tumor indication screening success rate of Zelin Bio’s ZeniMind platform:

As one of Zelin Bio’s three core technology platforms (ZeniFold Structural Biology Platform, ZeniMind AI Drug Discovery and Design Platform, ZeniScreen Clinically Relevant Disease Model Screening Platform), ZeniMind is primarily responsible for the key function of

[0][1][2]. Built on a self-developed AI algorithm system, this platform enables intelligent molecular generation and multi-objective parameter optimization, forming a closed-loop collaborative system of “structural analysis - AI design - disease model validation - structural backtracking validation” with the other two platforms [1][3].

According to publicly disclosed information, Zelin Bio currently has 8 R&D pipelines covering hematological tumors, solid tumors, central nervous system, and immune-inflammatory diseases, among other areas [0]. The ZeniMind platform plays a core role in solid tumor indication screening, mainly reflected in the following aspects:

1. Intelligent Molecular Generation
   : Realizes efficient design and optimization of candidate molecules through AI algorithms
2. Multi-Objective Parameter Optimization
   : Synchronously optimizes multi-dimensional indicators such as efficacy, pharmacokinetics, and safety
3. Closed-Loop Iterative Validation
   : Achieves continuous mutual verification and iterative optimization of computational and experimental data with the ZeniFold and ZeniScreen platforms [1][2]

[0][1][2][3]. The existing public information mainly presents the following characteristics:

Information Dimension	Disclosure Status
Platform technical principles and architecture	Qualitative descriptions available
Collaborative working mechanism	Fully disclosed
R&D efficiency improvement effect	Qualitative statement (“significant improvement”)
Specific success rate/efficiency indicators	Not publicly disclosed
Specialized screening data for solid tumors	Not publicly disclosed

To obtain detailed data on the solid tumor indication screening success rate of the ZeniMind platform, it is recommended to use the following channels:

1. Hong Kong Stock Exchange Prospectus
   : Zelin Bio formally submitted its listing application to the Hong Kong Stock Exchange in January 2026, and the prospectus may contain more detailed technical platform performance data [0][4]
2. Professional Pharmaceutical Database Query
   : Obtain special analysis reports on the company’s technical platforms through professional platforms such as Pharmcube (ByDrug) and Yaowang.com
3. Investor Relations Channel
   : Obtain technical platform performance evaluation reports through the company’s official investor relations department

As the core engine of Zelin Bio’s AI-driven drug discovery, the ZeniMind platform plays a key role in the solid tumor drug screening process. However, its

is currently commercially sensitive information not disclosed by the company. Existing public information only confirms that the platform has “significantly improved the efficiency of lead compound discovery and the quality of drug candidates” and has successfully supported the advancement of multiple small-molecule projects in development [1][2][3]. Specific quantitative indicators await the official prospectus document or special disclosure by the company.

---

[0] Sina Finance - “When AI Drug Development Cools Down, a ‘No-Nonsense’ Biotech is heading for the Hong Kong Stock Exchange” (https://cj.sina.cn/articles/view/7043693474/1a3d63ba202701dyrw)
[1] Qiming Venture Partners - “Qiming Star | Zelin Bio Secures Nearly RMB 600 Million in Series C Financing, Co-led by Qiming Venture Partners” (https://www.qimingvc.com/cn/news/赜灵生物C轮融资近6亿元，启明创投共同领投)
[2] ByDrug Pharmcube - “Zelin Bio Completes Nearly RMB 600 Million Series C Financing to Accelerate Global Innovative Drug R&D” (https://bydrug.pharmcube.com/news/detail/223960320042b9011025a5af164dc9a3)
[3] NetEase Finance - “61-Year-Old Female Professor from West China Hospital, Sichuan University Leads Zelin Bio Valued at RMB 3.4 Billion in Hong Kong Stock Exchange Listing Sprint” (https://www.163.com/dy/article/KJDIPVA80519GOPN.html)
[4] Sina Finance - “Tencent-Backed Zelin Bio Submits Listing Application to Hong Kong Stock Exchange: Valuation Grew Nearly 4x in 5 Years with No Product Sales Yet” (https://finance.sina.com.cn/roll/2026-01-14/doc-inhhhnwp8305370.shtml)